Personalised polytherapeutic healthcare is the future. Leading this future is Hevilo Life Sciences with the introduction of Bespoke Personalised Healthcare (BPH) – an exclusive concierge service for individuals with the resources to facilitate greater control over their healthcare decisions.
| SYDNEY, PRNewswire/ -- Personalised polytherapeutic healthcare is the future. Leading this future is Hevilo Life Sciences with the introduction of Bespoke Personalised Healthcare (BPH) – an exclusive concierge service for individuals with the resources to facilitate greater control over their healthcare decisions. Addressing the treatment and prevention of degenerative diseases, BPH is a hyper-personalised polytherapeutic offering. “In this day and age where biomarkers, -omics technologies, and big data are empowering practitioners and patients to deliver and experience optimal healthcare, growing numbers are reluctant to accept generalised one-size-fits-all treatments that fail to accommodate an individual’s genes, lifestyle and environment,” says Sophia Barker, Director of Hevilo Life Sciences BPH. “With BPH, in an environment of upmost privacy and discretion, individuals who suffer from, or are predisposed to, one or more degenerative diseases – Alzheimer’s Disease (AD), Multiple Sclerosis (MS), Parkinson’s Disease (PD), Type-1 Diabetes (T1D), Osteoarthritis (OA), Crohn’s Disease (CD) and beyond – can better position themselves to receive the targeted healthcare they need, when they need it, without delay.” Following a successful 9-month North American pilot program, BPH is now available globally, providing individuals – proactively or reactively – with an opportunity to benefit from one-on-one treatments within reduced time frames. Tailored exclusively to an individual’s disease and/or condition, the non-stratified personalised approach supports the development of targeted polytherapeutic treatments with unprecedented efficacy and effectiveness. For the individual, this can mean fewer treatments, of lesser duration, with minimal if any side effects. “Having overcome the challenge of compressing bench-to-bedside timeframes, our next challenge is to scale our novel polytherapeutic offering and treatments to make them affordable and accessible to greater numbers of people. Strategic partnerships and collaborations are vital to accelerating this realisation,” adds Sophia Barker. For more information about Hevilo Life Sciences Bespoke Personalised Healthcare, visit https://hevilo.com/bespoke. About Hevilo Life Sciences Media & Press Contact John Anthony
SOURCE Hevilo Life Sciences |
View original content:
